New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
DFB Pharmaceuticals Inc.
www.dfb.com
Latest From DFB Pharmaceuticals Inc.
Symetis: Well-Positioned Next-Generation TAVI Player
Now among the most promising of an emerging group of second-generation transcatheter aortic valve implantation (TAVI) companies, Symetis didn’t start out that way. It began as a cell therapy company, but its initial technology failed. On the verge of running out of money, CEO Jacques Essinger, PhD, engineered a change of direction that ultimately turned Symetis into a TAVI company with the kinds of advantages that may provide it with a competitive advantage.
Company Information
- Industry
-
Medical Devices
- Surgical Equipment & Devices
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- DFB Pharmaceuticals Inc.
- Senior Management
- H. Paul Dorman, Chmn. & CEO
- Contact Info
-
DFB Pharmaceuticals Inc.
Phone: (817) 900-4000
3909 Hulen St.
Fort Worth, TX 76107
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DFB Pharmaceuticals Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice